Oliver Pullig
Papers
1
Total Citations
13
H-Index
1
About
Oliver Pullig is a leading figure in the translational development of Advanced Therapy Medicinal Products (ATMPs), with a specific focus on Tissue Engineered Products (TEPs) for cartilage repair. His work bridges the critical gap between laboratory-scale research and clinical-grade manufacturing, addressing one of the most formidable bottlenecks in regenerative medicine. Pullig’s major contribution lies in the design and validation of automated, scalable production platforms that can transition TEPs from single-batch processes to mass production, a feat essential for late-stage clinical trials and eventual commercialization. His most-cited work, "From Single Batch to Mass Production–Automated Platform Design Concept for a Phase II Clinical Trial Tissue Engineered Cartilage Product" (2021, 13 citations), exemplifies this focus, outlining a robust manufacturing strategy for a cartilage product targeting unmet clinical needs. By tackling the engineering and regulatory challenges of ATMP scale-up, Pullig’s research directly impacts the feasibility of bringing living, tissue-based therapies to patients suffering from progressive and chronic diseases. His achievements underscore a career dedicated to making regenerative treatments not just possible, but practical and accessible.
Research Focus
Key Achievements
Top Papers
- 1